Bartlett & Co’s GSK GSK Stock Holding History

Bartlett & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$49K	Sell	1,319 -240	-15%	-$8.62K	﹤0.01%	709
2023 Q3	$57K	Hold	1,559	–	–	﹤0.01%	640
2023 Q2	$56K	Hold	1,559	–	–	﹤0.01%	649
2023 Q1	$56K	Hold	1,559	–	–	﹤0.01%	554
2022 Q4	$55K	Hold	1,559	–	–	﹤0.01%	564
2022 Q3	$46K	Sell	1,559 -159	-9%	-$6.03K	﹤0.01%	576
2022 Q2	$94K	Buy	1,718 +159	+10%	+$8.78K	﹤0.01%	468
2022 Q1	$86K	Buy	+1,559	New	+$84.7K	﹤0.01%	505
2021 Q4	–	Sell	-1,559	Closed	-$74K	–	587
2021 Q3	$74K	Sell	1,559 -775	-33%	-$38.9K	﹤0.01%	460
2021 Q2	$116K	Hold	2,334	–	–	﹤0.01%	391
2021 Q1	$104K	Sell	2,334 -796	-25%	-$36.1K	﹤0.01%	405
2020 Q4	$144K	Sell	3,130 -896	-22%	-$41.2K	﹤0.01%	357
2020 Q3	$189K	Hold	4,026	–	–	﹤0.01%	316
2020 Q2	$205K	Hold	4,026	–	–	0.01%	305
2020 Q1	$191K	Buy	+4,026	New	+$215K	0.01%	296
2019 Q3	$176K	Buy	3,290 +980	+42%	+$50.4K	﹤0.01%	341
2019 Q2	$116K	Hold	2,310	–	–	﹤0.01%	310
2019 Q1	$121K	Sell	2,310 -1,696	-42%	-$84.7K	﹤0.01%	293
2018 Q4	$191K	Hold	4,006	–	–	0.01%	253
2018 Q3	$201K	Hold	4,006	–	–	0.01%	258
2018 Q2	$202K	Sell	4,006 -442	-10%	-$22.3K	0.01%	252
2018 Q1	$217K	Buy	4,448 +442	+11%	+$20.6K	0.01%	245
2017 Q4	$178K	Hold	4,006	–	–	0.01%	265
2017 Q3	$203K	Hold	4,006	–	–	0.01%	252
2017 Q2	$216K	Hold	4,006	–	–	0.01%	244
2017 Q1	$211K	Hold	4,006	–	–	0.01%	249
2016 Q4	$193K	Sell	4,006 -220	-5%	-$10.9K	0.01%	253
2016 Q3	$228K	Hold	4,226	–	–	0.01%	239
2016 Q2	$229K	Sell	4,226 -160	-4%	-$8.43K	0.01%	238
2016 Q1	$222K	Hold	4,386	–	–	0.01%	238
2015 Q4	$221K	Hold	4,386	–	–	0.01%	240
2015 Q3	$211K	Hold	4,386	–	–	0.01%	241
2015 Q2	$228K	Hold	4,386	–	–	0.01%	242
2015 Q1	$253K	Buy	4,386 +240	+6%	+$13.8K	0.01%	238
2014 Q4	$222K	Sell	4,146 -240	-5%	-$13.4K	0.01%	247
2014 Q3	$252K	Hold	4,386	–	–	0.01%	232
2014 Q2	$293K	Sell	4,386 -40	-0.9%	-$2.71K	0.01%	232
2014 Q1	$296K	Sell	4,426 -1,400	-24%	-$94.6K	0.01%	228
2013 Q4	$389K	Hold	5,826	–	–	0.02%	203
2013 Q3	$365K	Sell	5,826 -80	-1%	-$5.15K	0.02%	202
2013 Q2	$369K	Buy	+5,906	New	+$375K	0.02%	196

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bartlett & Co's GSK Position: Q4 2023 in Review

Bartlett & Co reduced its GSK (GSK) stake by 15% in Q4 2023, selling an estimated $8.62K and leaving 1,319 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

Bartlett & Co first reported a position in GSK in Q2 2013 and has held it in 41 quarters since. The position peaked at $389K in Q4 2013. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.

Bartlett & Co held 1,319 shares of GSK worth $49K as of Q4 2023.
Bartlett & Co sold 240 GSK shares in Q4 2023, an estimated $8.62K.
GSK made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #709 holding.
Bartlett & Co first reported a position in GSK in Q2 2013 and has held it in 41 quarters since.
Bartlett & Co's GSK position peaked at $389K in Q4 2013.
895 funds tracked by Wall St. Rank held GSK as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.